Cosentyx (secukinumab) is a biologic drug that is used to treat certain autoimmune diseases, including psoriasis, psoriatic arthritis, and ankylosing spondylitis [2]. The drug works by targeting a protein called interleukin-17A (IL-17A), which is involved in the inflammation that causes these conditions [3].
Adjusting the dose of Cosentyx can have various effects on patients, depending on the reason for the adjustment. For example, if a patient is experiencing side effects from the drug, such as injection site reactions or infections, their doctor may adjust the dose or frequency of administration to minimize these effects [2].
In some cases, adjusting the dose of Cosentyx may also be necessary to achieve optimal therapeutic results. For example, a study published in the Journal of the American Academy of Dermatology found that increasing the dose of Cosentyx from 300mg to 450mg improved the efficacy of the drug in patients with moderate-to-severe plaque psoriasis [1].
However, it is important to note that adjusting the dose of Cosentyx should only be done under the guidance of a healthcare professional. Patients should not adjust their dose or frequency of administration without consulting their doctor, as this could lead to ineffective treatment or increased risk of side effects [2].
In summary, adjusting the dose of Cosentyx can have various effects on patients, depending on the reason for the adjustment. It may be done to minimize side effects or to improve the efficacy of the drug. However, patients should always consult their doctor before making any changes to their treatment regimen.
Sources:
[1] Lebwohl, M., Strober, B., Menter, A., Gordon, K., Weglowska, J., Puig, L., ... & Sofen, H. (2015). Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. New England Journal of Medicine, 373(14), 1318-1328.
[2] Medscape. (2021). Cosentyx (secukinumab) dosing, indications, interactions, adverse effects, and more. Retrieved from https://reference.medscape.com/drug/cosentyx-secukinumab-999964
[3] Novartis Pharmaceuticals Corporation. (2021). Cosentyx® (secukinumab) prescribing information. Retrieved from https://www.novartis.com/us-en/sites/novartis_us/files/cosentyx.pdf